The builder of a small red tablet dictated to provide a singular condition is raking in hundreds of millions of dollars a year as it aggressively targets thin and aged nursing home residents for whom a drug might be nonessential or even unsafe, a CNN review has found.
What should we examine next?
Email Blake Ellis and Melanie Hicken
Do you have an unusual story to tell? E-mail firstname.lastname@example.org